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Introduction
The trajectory of research on cholesterol has been that epidemiology 
and basic science informed the need for efficacy trials, which 
led to clinical and public health guidelines. The implementation 
of the guidelines led to the curve being successfully turned from 
increasing to decreasing population rates of cardiovascular disease 
(CVD). Cholesterol and heart disease are one of the most intensively 
researched areas of science. Therefore, this review only touches on 
a few of the topics that are most salient to public health. 
Lipids, lipoproteins and lipoprotein particles 
Decades ago, the clinical focus changed from total cholesterol (TC) 
levels to low-density lipoprotein (LDL) cholesterol levels, and high-
density lipoprotein (HDL) cholesterol levels, i.e. “bad” and “good” 
cholesterol, respectively. It is now known that “bad” and “good” 
cholesterol are actually lipoprotein particles, with the atherogenic 
“bad” particles comprising the chylomicron remnants from the 
intestinal absorption of triglycerides and cholesterol, plus very low-
density lipoprotein (VLDL), intermediate-density lipoprotein (IDL) 
and LDL particles, all of which derive from hepatic synthesis and 
the excretion of VLDL cholesterol, with the subsequent removal of 
triglycerides during circulation to yield smaller, more cholesterol-
dense IDL and LDL particles. These particles deliver lipids to the 
peripheral tissue, and LDL is eventually taken up again by the 
liver, mainly mediated by binding to the LDL receptor. The “good” 
HDL particles are also produced and excreted by the liver, take up 
cholesterol from the peripheral tissue, and exchange cholesterol 
with the LDL particles. LDL particles are “bad” because they promote 
atherogenesis, with the particles moving into the intima of the artery 
through a passive, gradient-driven process, i.e. the more particles 
there are, the more particles enter the intima. The particles are 
retained by binding to proteoglycans and undergo oxidation, thereby 
setting in motion a cascade of factors which lead to endothelial 
dysfunction.1 Circulating monocytes adhere to the dysfunctional 
endothelium and migrate into the subendothelium, where they 
phagocytose the oxidised LDL particles to form foam cells. The foam 
cells, debris from dead cells, and deposition of cholesterol crystals 
form the core of the lipid-laden vulnerable plaques, whose rupture 
or erosion precipitate an acute coronary syndrome. HDL particles are 
“good” because they inhibit atherogenesis by promoting cholesterol 
efflux, and by inhibiting adhesion molecule expression and the 
oxidation of LDL.2 
Historically, triglycerides, mainly in chylomicron remnants and 
VLDL particles; and LDL and HDL cholesterol have been used as 
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biomarkers. LDL cholesterol was calculated from the measurement 
of TC, HDL cholesterol and triglycerides. While these remain useful 
biomarkers, the number of VLDL, LDL and HDL particles can now be 
more directly measured using nuclear magnetic resonance imaging. 
The number of LDL particles appears to be more important than the 
size thereof. Forty-one of 50 studies showed a significant association 
between LDL particle size and CVD, but only 12 remained significant 
after multivariate adjustment for other risk factors.3,4 
On the other hand, all of the four studies that examined the 
association of the LDL particle number with CVD were significant 
in both univariate and multivariate models. The measurement of the 
particle number is not universally available, but the measurement of 
apoliprotein B for VLDL, IDL and LDL particles, and apoliprotein AI for 
HDL particles; or even more simply, the measurement of non-HDL 
cholesterol and HDL cholesterol, provides readily available surrogate 
measures of “bad” and “good” particle numbers. These can be 
measured in the fasting or non-fasting state, since they do not 
depend on the measurement of triglycerides and the calculation of 
LDL cholesterol. Calculated LDL cholesterol is subject to inaccuracies 
at high levels of triglycerides and low levels of directly measured 
LDL cholesterol. Non-fasting samples have an additional advantage 
in that they better reflect the risk associated with triglyeride-rich 
remnant particles.5 The hazard ratios for chronic heart disease (CHD) 
per standard deviation of non-HDL cholesterol were equivalent to 
those of the apoliprotein B measurements, and the hazard ratios for 
the HDL apoliprotein were equivalent to those of the apoliprotein AI 
measurements in a meta-analysis of 302 430 individuals without 
prior vascular disease in 68 long-term prospective studies.6  
Triglycerides, HDL cholesterol and non-HDL cholesterol were 
significantly associated with CHD in models adjusted for age and 
sex. However, after further adjustment for several risk factors, HDL 
cholesterol and non-HDL cholesterol, but not triglycerides, remained 
significantly associated with CHD. The adjusted hazard ratios for 
CHD were 0.99 [95% confidence interval (CI): 0.94-1.05], 0.78 
(95% CI: 0.74-0.82) and 1.50 (95% CI: I.39-1.61) for triglycerides, 
HDL cholesterol and non-HDL cholesterol, respectively. The risk 
of CHD related to non-HDL cholesterol down to levels of 130 mg/
dl (3.3 mmol/l), corresponded to an LDL cholesterol of ~80 mg/dl 
(2 mmol/l). The increased risk for CHD associated with non-HDL 
cholesterol was evident in all of the age groups, including those aged 
70+, in both females and males, and in those with and without a 
history of diabetes. The hazard ratio for CHD was 1.38, compared 
to 1.42, for non-HDL cholesterol, in a subset with directly measured 
LDL cholesterol.
Thus, while LDL cholesterol remains a clinically useful marker for 
CHD risk, non-HDL cholesterol may be more biologically relevant 
since it is a proxy for the atherogenic particle number, is not 
subject to the biases introduced by calculating LDL cholesterol in 
the conventional assay, and can be measured in both fasting and 
non-fasting subjects. In these analyses, non-HDL cholesterol was 
strongly and independently associated with CHD, irrespective of age, 
sex or diabetes status. Triglycerides were not an independent risk 
factor in these analyses. 
Low-density lipoprotein cholesterol causes coronary 
heart disease
LDL cholesterol is more than a risk marker. It is also a causal risk 
factor, as demonstrated by genetic studies and clinical trials. The 
estimated hereditability of LDL cholesterol is in the range of 40-50%, 
and a small number of rare monogenic conditions contributing  to the 
hereditability lead to either very high (LDLR, APOB and LDLRAP1) or 
low (MTTP, APOB, PCSK9) LDL cholesterol levels.7 The cardiovascular 
implications of lifelong genetically determined high or low LDL 
cholesterol levels have been extensively studied in the case of LDL 
receptor and proprotein convertase subtilisin/kexin type 9 (PCSK9) 
mutations, respectively. Loss-of-function mutations in the LDL 
receptor cause familial hypercholesterolaemia (FH), which occurs in 
1:500 individuals worldwide, but has a higher frequency of ~1:70 
to 1:100 in Afrikaners.8,9 It has been demonstrated in population-
based studies that Afrikaners with heterozygous FH typically have 
LDL cholesterol  levels in excess of 6 mmol/l, and the smaller 
number of patients with homozygous FH seen in lipid clinics typically 
have levels of approximately 20 mmol/l. Untreated heterozygous 
FH is associated with the early onset of myocardial infarction and 
accounts for roughly one quarter of early-onset myocardial infarction 
in Afrikaners. In a Japanese study, the average age of myocardial 
infarction in male heterozygotes was in the third decade of life, and in 
females in the fourth decade of life. The average age at death was 26 
years in homozygotes.10 Statins block hepatic cholesterol synthesis 
and increase the number of LDL receptors, thereby lowering LDL 
cholesterol levels and reducing the risk of myocardial infarction in 
patients without FH, in patients with heterozygous FH, and also in 
some, but not all cases, of homozygous FH. 
By way of contrast, loss-of-function mutations of the PCSK9 gene 
are associated with lifelong lower levels of LDL cholesterol and a 
much reduced risk of myocardial infarction. A 28% reduction in 
LDL cholesterol was associated with an 88% reduction in the risk 
of CHD in African Americans in a seminal study by Cohen et al.11 
A smaller 15% reduction in LDL cholesterol in whites due to a 
different allele was associated with a 47% reduction in CHD risk. The 
authors concluded that “moderate lifelong reduction in the plasma 
level of LDL cholesterol is associated with a substantial reduction 
in the incidence of coronary events, even in populations with a 
high prevalence of non-lipid-related cardiovascular risk factors”. 
A Mendelian randomisation meta-analysis of the effect of long-term 
exposure to lower LDL cholesterol, beginning early in life, on the 
risk of CHD, found that nine polymorphisms in six different genes, 
including PCSK9, were associated with a consistent reduction in 
the risk of CHD, which was proportional to the variable reductions 
in LDL cholesterol associated with individual polymorphisms, and 
independent of any changes in triglycerides or HDL cholesterol. 
There was a highly significant 54% reduction in CHD risk for each 
millimole per litre reduction in LDL cholesterol.7
The risk reduction in Mendelian randomisation studies is substantially 
greater than that obtained by statin treatment started later in life. 
An average reduction of 24% in the risk of major coronary events 
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for each millimole per litre reduction in LDL cholesterol from statins 
over five years was shown in a meta-analysis of statin trials.12 
This individual-level meta-analysis of 90 056 participants in 14 
randomised trials on statins showed that the CHD risk reduction 
was proportional to the degree of lipid lowering obtained, and that 
significant risk reductions were obtained in patients with and without 
previous CHD, in older (> 65 years) and younger males and females, 
whether or not they were on treatment for hypertension or diabetes. 
Additionally, statin treatment lowered the risk of a stroke and total 
mortality.
In an updated meta-analysis of an even larger number of subjects 
(n = 174 149 in 27 trials), the Cholesterol Treatment Trialists’ 
collaborators showed that reducing LDL cholesterol was effective 
in reducing CHD, even in persons with a low baseline risk (who 
would not be considered for treatment according to some current 
guidelines), and that the benefits of statins exceeded the risks.13 
For example, in low-risk subjects with a < 10% five-year risk of 
major vascular events over five years for every 1 000 individuals, 
each millimole per litre of LDL cholesterol reduction on statin 
therapy could result in 11 fewer major vascular events, five more 
diagnoses of diabetes (and 0.2 fewer major vascular events being 
avoided because of the risk associated with diabetes), and 0.5 more 
diagnoses of myopathy and haemorrhagic strokes. In other words, 
even if diabetes was considered to be a condition that was as serious 
as a major vascular event, there would be twofold more benefit than 
risk in low-risk subjects. In high-risk subjects with a 20-30% five-
year risk of major vascular events, 28 fewer major vascular events 
would occur while they were on statin treatment, and there would be 
five times more benefit than risk.     
The findings from the Mendelian randomisation studies and clinical 
trials, showing CHD risk reductions proportional to the degree 
of cholesterol lowering and duration of exposure, demonstrate 
conclusively that LDL cholesterol is a causal risk factor for CHD. In 
particular, the fact that 88% of CHD events could be avoided by a 
relatively modest 28% lower lifelong exposure to LDL cholesterol, 
even in subjects with multiple other risk factors, strongly supports 
the view that LDL cholesterol is a sufficient risk factor, i.e. no other 
factor needs to be invoked to explain the greater part of CHD risk. 
By way of contrast, the Mendelian randomisation studies and clinical 
trials have not provided conclusive support for causality in the cases 
of triglycerides or HDL cholesterol.
Implementation
Public health and clinical guidelines, based on knowledge of the 
effects of diet and statins on serum cholesterol, and the relationship 
of serum cholesterol to CHD risk, have been effective in lowering 
population cholesterol levels and CHD risk in many countries. One of 
the more striking examples is from Finland, which towards the end 
of the 1960s, had the highest CHD mortality in the world. However, 
over the course of 30 years, changes in diet were encouraged using 
a population strategy, especially with regard to the type and amount 
of fat consumed, with an emphasis on the intake of fresh vegetables 
and fruit. The result was an 80% reduction in the rate of CHD death.14 
Seventy-five per cent of the CHD risk reduction was attributable to 
changes in lifestyle, and in particular, the 21% lowering of serum 
cholesterol levels. Deaths due to heart disease, including heart 
failure, in the USA, increased steeply from 1900-1970, after which 
they levelled off and started dropping in 1990.15 The decline in CHD 
death rates in the USA has been equally impressive, with a 70% 
decline from 1970-2000. The major reason for the slower decline in 
total heart disease, than in that for CHD deaths, is that deaths from 
heart failure have continued to be high because CHD case fatality 
rates have improved, leaving a larger number at risk of developing 
heart failure. The decline in CHD was preceded by lowering the 
population dietary fat intake, particularly that of saturated fat, from 
1965 onwards, accompanied by the lowering of population serum 
cholesterol levels.15,16 The changes in population fat intake were 
preceded by the publication in 1957 by the Framingham Heart Study 
in which serum cholesterol was established to be as a risk factor, as 
well as a series of publications from the Anti-Coronary Club study, 
which showed the cholesterol-lowering effect of what was dubbed 
the “prudent diet” (30% total fat with approximately one third of 
each of the polyunsaturated, monounsaturated and saturated fats), 
plus recommendations from the American Heart Association and the 
American Medical Association encouraging the use of a “prudent 
diet” in high-risk patients.17-19 These recommendations were 
incorporated in the 1977 dietary goals for Americans.20 
The authors of the dietary goals, noting the decreasing intake of 
fruit, vegetables and wholegrains, and the increased intake of 
meat, fat and sugary drinks over the preceding 50 years, made 
recommendations to:
•	 Increase the consumption of fruit, vegetables and wholegrains.
•	 Decrease the consumption of meat, and increase the consumption 
of poultry and fish.
•	 Decrease the consumption of foods high in fat, and partially 
substitute polyunsaturated fat for saturated fat.
•	 Substitute non-fat milk for whole milk.
•	 Decrease the consumption of butterfat, eggs and other high-
cholesterol foods.
•	 Decrease the consumption of sugar and foods high in sugar 
content.
•	 Decrease the consumption of salt and foods high in salt content.
The advice to reduce total fat intake would necessarily lead to an 
increase in carbohydrate intake, and this is what happened in many 
countries. More recent guidelines place less emphasis on total fat 
intake, and more on the quality of fat and that of carbohydrates.21 
Nevertheless, it is likely that the dietary goals further assisted 
in the already ongoing decline in CHD risk in the USA. Public 
recommendations in the UK lagged behind those in the USA. Declines 
in total fat consumption occurred in the mid 1970s and subsequent 
declines in CHD death rates were delayed to the mid 1980s.22 More 
recently, the introduction of statin drugs in the late 1980s and 
the improved treatment of coronary disease have maintained the 
downward trajectory in CHD mortality. Approximately half of the 
decline in CHD mortality in the USA may be attributable to reductions 
in major risk factors, and roughly half to improved treatment.23 
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Conclusion
The principal conclusion of this brief review is that cholesterol levels 
are associated with the increased risk of coronary heart disease, 
even at “normal” levels of cholesterol, in both men and women 
of all ages. Biology, in the form of genetic studies, supports the 
causal role of LDL cholesterol, as does the fact that the treatment 
of elevated levels reduces risk in individuals. Finally, the adoption 
of knowledge on the dietary effects of serum cholesterol and the 
improved management of elevated levels has led to declines in the 
CHD population risk. 
Declaration
The views expressed in the article do not necessarily represent the 
views of the National Heart, Lung, and Blood Institute, nor the United 
States Department of Health and Human Services.
Conflict of interest
The author declares that there were no conflicting interests which 
may have inappropriately influenced him when writing this article.
References
1. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating 
process in atherosclerosis: update and therapeutic implications. Circulation. 
2007;116:1832-1844.
2. Cockerill GW, Rye KA, Gamble JR, et al. High density lipoproteins inhibit cytokine-
induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc 
Biol. 1995;15(11):1987-1994.
3. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. 
QJM. 2006;99(1):1-14. 
4. Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of 
lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study. 
Arterioscler Thromb Vasc Biol. 2002;22(7):1175-1180.
5. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-
function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 
2014;371(1):32-41.
6. The Emerging Risk Factors Collaboration, Di Angelantario E, Sarwar N, et al. Major lipids, 
apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993-2000.
7. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density 
lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a 
Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631-2639.
8. Steyn K, Goldberg YP, Kotze MJ, et al. Estimation of the prevalence of familial 
hypercholesterolaemia in a rural Afrikaner community by direct screening for three 
Afrikaner founder low density lipoprotein receptor gene mutations. Hum Genet. 
1996;98(4):479-484.
9. Seftel HC, Baker SG, Sandler MP, et al. A host of hypercholesterolaemic homozygotes in 
South Africa. Br Med J. 1980;281(6241):633-636.
10. Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of coronary heart disease in 
familial hypercholesterolemia. Circulation. 1989;79(2):225-332.
11. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL 
and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-1271.
12. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering 
treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized 
trials of statins. Lancet. 2005;366(9493):1267-1278.
13. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, et al. 
The effects of lowering LDL cholesterol with statin therapy in people at low risk of 
vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 
2012;380(9841):581-590.
14. Vartiainen E, Laatikainen T, Peltonen M, et al. Thirty-five-year trends in cardiovascular 
risk factors in Finland. Int J Epidemiol. 2010;39(2):504-518.
15. Go AS, Mozzafarian D, Roger VL, et al. Heart disease and stroke statistics - 2013 update: 
a report from the American Heart Association. Circulation. 2013:127(1):e6-e245.
16. Stephen AM, Wald NJ. Trends in individual consumption of dietary fat in the United States 
1920-1984. Am J Clin Nut. 1990;52(2):457-469.
17. Dawber TR, Moore FE, Mann GV. Coronary heart disease in the Framingham Study. Am J 
Public Health. 1957;47(4 Pt 2):4-24. 
18. Singman HS, Berman SN, Cowell C, et al. The Anti-Coronary Club: 1957-1972. Am J Clin 
Nutr. 1980;33(6):1183-1191. 
19. Page IH, Allen EV, Chamberlain FL, Keys A, et al. Dietary fat and its relation to heart 
attacks and strokes. Circulation, 1961;23:133-136.
20. Select Committee on Nutrition and Human Needs, United States Senate. Dietary goals for 
the United States. Washington: US Government Printing Office, 1977.
21. Dietary Guidelines Advisory Committee. Report of the Dietary Guidelines Advisory 
Committee on the dietary guidelines for Americans, 2010. Washington: US Department 
of Agriculture, Agricultural Research Service; 2010.
22. Stephen A, Sieber GM. Trends in individual fat consumption in the UK 1900-1985. Br J 
Nutr. 1994;71(5):775-788. 
23. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in US deaths from coronary 
disease, 1980-2000. N Engl J Med. 2007;356(23):2388-2398.
